DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Biotech Radar · July 1, 2026

Biotech Radar July 1, 2026: $CANF, $ABVX, $SXTP and $MODD Lead Today’s Catalyst Watch

Today’s biotech tape is built around four very different catalyst profiles: a small-cap oncology survival signal, a late-stage ulcerative colitis story with an NDA path but offering noise, a micro-cap infectious-disease program cleared to continue after an independent safety review, and a diabetes medtech platform moving through both commercial rollout and new FDA software-enhancement review.

Focus: Clinical and regulatory catalysts Style: Educational market watch Tickers: $CANF · $ABVX · $SXTP · $MODD Not financial advice
Top clinical spark
$CANF

Can-Fite reported that namodenoson met the primary safety endpoint in a Phase 2a pancreatic cancer study and showed durable survival observations in advanced disease.

Late-stage heavyweight
$ABVX

Abivax remains a serious late-stage UC story after obefazimod Phase 3 maintenance data, but today’s ADS offering halt keeps dilution and pricing in focus.

Safety continuation watch
$SXTP

60 Degrees Pharma received a positive DSMB recommendation to continue the B-FREE Phase 2 tafenoquine study after review of early safety data.

Medtech FDA update
$MODD

Modular Medical submitted Pivot software enhancements to the FDA after recent commercial availability and first-patient-use updates for its tubeless insulin patch pump.

Executive Takeaway: Four Catalysts, Four Very Different Risk Profiles

The key to today’s radar is not to treat all four names as the same kind of trade. $CANF is a small-cap oncology catalyst with a fresh Phase 2a pancreatic cancer update. $ABVX is a late-stage inflammatory disease story where the science is strong but financing optics are now part of the setup. $SXTP is a micro-cap infectious-disease watch where the news is positive for trial continuation, but not yet efficacy proof. $MODD is technically medtech rather than biotech, but it deserves radar space because diabetes device adoption can generate strong market attention when regulatory and commercial milestones arrive close together.

This is exactly the type of day where headline discipline matters. A positive safety endpoint in oncology is not the same as a registrational efficacy win. A DSMB continuation recommendation is not the same as a successful Phase 2 efficacy readout. A commercial medtech launch is not the same as broad reimbursement traction. And a late-stage Phase 3 success can still trade with pressure when an offering is being priced.

TickerCompanyToday’s Radar AngleWhy It MattersMain RiskNext Watchpoint
$CANFCan-Fite BioPharmaPhase 2a pancreatic cancer update for namodenosonSafety endpoint met, with durable survival observations in a difficult, heavily pretreated PDAC populationSmall open-label study; survival signal needs controlled confirmationPhase 2b combination study design, timing, partner interest, future data presentation
$ABVXAbivaxObefazimod Phase 3/NDA setup plus ADS offering overhangStrong UC maintenance data and planned Q4 2026 NDA submission keep it institutionally relevantFinancing/dilution optics and post-data volatilityFinal ADS pricing, cash runway, NDA preparation, Crohn’s Phase 2b mid-2027
$SXTP60 Degrees PharmaceuticalsIndependent DSMB recommends continuation of B-FREE Phase 2 studyNo safety concerns identified in the first six patients through Day 30, allowing tafenoquine development in chronic babesiosis to continueEarly safety review only; tafenoquine is not FDA-approved for babesiosisEnrollment, Day 90 fatigue endpoint, molecular confirmation rates, future safety/efficacy updates
$MODDModular MedicalFDA submission for Pivot software enhancements after commercial rolloutCore Pivot form factor is cleared and in the market; software upgrades may improve customization and user experienceFDA review timing, adoption, reimbursement, manufacturing scale and funding riskFDA feedback, patient onboarding, physician-office rollout, Q4 2026 commercial expansion

$CANF — Can-Fite: The Day’s Cleanest Small-Cap Oncology Spark

Can-Fite BioPharma is the most obvious first name in today’s radar because the update is directly clinical, directly oncology-focused and easy for the market to understand. The company announced that its Phase 2a study of namodenoson in advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes in advanced disease.

The open-label Phase 2a study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received namodenoson as third-line treatment, five as second-line treatment and one as fourth-line treatment. That detail matters because pancreatic cancer after prior systemic therapy is one of the toughest settings in oncology.

The company reported that namodenoson was well tolerated, with a safety profile consistent with prior clinical trials. Following extended follow-up, Can-Fite performed an updated survival analysis in the third-line population, focusing on eight patients who survived at least two months after treatment initiation. In those eight evaluable third-line patients, median overall survival exceeded five months, 62.5% survived five months or longer, and 37.5% survived seven months or longer. The company also highlighted that a second-line patient remains alive more than 18 months after starting namodenoson.

Radar reading: $CANF has the cleanest small-cap clinical headline of the group, but the study is small and open-label. This is a survival-signal story that supports further development, not a definitive efficacy verdict.

What looks positive

The safety endpoint was met, no new safety issue dominates the update, and the survival observations give Can-Fite a stronger rationale to move namodenoson into additional pancreatic cancer development.

What keeps risk high

The dataset remains small and uncontrolled. Durable survival in selected evaluable patients is encouraging, but larger controlled studies are needed to separate drug effect from patient-selection noise.

Why namodenoson is getting attention

Namodenoson is a small orally bioavailable drug that binds selectively to the A3 adenosine receptor. Can-Fite’s development rationale is that A3AR is highly expressed in diseased cells while showing low expression in normal cells, a profile the company links to the drug’s safety history. The company also says it plans to advance namodenoson into a Phase 2b combination study with chemotherapy, supported by preclinical data suggesting that namodenoson may enhance chemotherapeutic anti-tumor activity.

That next step is the key. A monotherapy signal in advanced pancreatic cancer can create market excitement, but the real clinical question is whether namodenoson can add value in a more structured combination setting. If Can-Fite can clarify the Phase 2b design, timeline, enrollment criteria and comparator strategy, the story becomes easier for investors to model.

$CANF trading interpretation

$CANF is the type of small-cap oncology name that can move quickly because the headline has the right ingredients: cancer, safety endpoint, survival observations, small market-cap profile and a future Phase 2b development path. The caution is just as clear: momentum can run ahead of the evidence. The correct classification is “early oncology signal with high headline sensitivity.”

$ABVX — Abivax: Strong Phase 3 Story, But Offering Optics Matter

Abivax is the most advanced clinical story in today’s group, but it is also the one that requires the most nuance. The fundamental biotech story remains strong: obefazimod has produced major Phase 3 maintenance data in ulcerative colitis, and the company remains on track for a planned NDA submission in the fourth quarter of 2026. The trading story, however, is complicated by the ADS public offering and the temporary halt of ordinary shares on Euronext Paris on July 1, 2026.

On June 1, Abivax reported that both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint of clinical remission at Week 44 in the Phase 3 ABTECT maintenance trial. The company reported placebo-adjusted clinical remission rates of 39.3% for the 25 mg dose and 40.3% for the 50 mg dose, with p-values below 0.0001. Both doses also met key secondary endpoints, including endoscopic improvement, endoscopic remission, corticosteroid-free clinical remission and sustained clinical remission.

On June 29, Abivax added another useful layer with ABTECT Maintenance Part 2 results. In a more refractory UC population, 37.2% of induction non-responders achieved clinical remission and 34.5% achieved endoscopic remission at Week 44 following continued 50 mg treatment. Dose escalation to obefazimod 50 mg recaptured clinical remission in 45.5% of patients who relapsed during ABTECT Maintenance Part 1.

Radar reading: $ABVX is not a micro-cap lottery ticket. It is a late-stage regulatory setup. The science looks materially stronger than the typical daily radar name, but the ADS offering means dilution, pricing and cash runway can dominate near-term trading.

Why the July 1 halt matters

On July 1, Abivax requested a temporary trading halt of its ordinary shares on Euronext Paris from 9:00 a.m. CEST. The company said the halt was connected to its U.S. public offering of American Depositary Shares and was intended to allow confirmation of allocations and announcement of final pricing. Trading was expected to resume around 3:30 p.m. CEST.

This does not invalidate the clinical setup. It simply changes the short-term market lens. When a biotech with strong data raises capital, the market usually asks three questions before refocusing on the science: At what price? How much dilution? Does the financing sufficiently fund the next value-creating steps?

What looks positive

Obefazimod has a coherent late-stage profile: strong Phase 3 maintenance efficacy, supportive refractory-patient data and a planned Q4 2026 NDA submission.

What needs monitoring

The offering can temporarily dominate sentiment. Even strong clinical data can trade poorly when investors are digesting new share supply and financing terms.

$ABVX trading interpretation

$ABVX deserves radar space because it is one of the more serious late-stage biotech stories in the group. The bullish view is that obefazimod may become an important oral UC therapy if approved. The cautious view is that financing risk and post-data volatility can create ugly short-term tape even when the clinical package remains strong. The cleanest classification is “science strong, financing noisy.”

$SXTP — 60 Degrees Pharma: Positive DSMB Continuation, Not Yet Efficacy Proof

60 Degrees Pharmaceuticals is the most speculative biotech name in today’s radar. The company announced that an independent Data Safety Monitoring Board recommended continuation of the B-FREE Phase 2 study of tafenoquine for chronic babesiosis patients with severe fatigue. This is a positive operational and safety milestone, but it must be described correctly: this is not a completed efficacy readout.

The DSMB reviewed safety data from the first six patients from baseline through Day 30 and identified no safety concerns that would stop the study. The trial is being conducted at the Icahn School of Medicine at Mount Sinai and evaluates the ARAKODA tafenoquine regimen in patients with severe persistent fatigue and laboratory evidence of exposure to Babesia species.

The dosing schedule described by the company uses a loading dose of 200 mg per day for four days, followed by 200 mg weekly through Day 90. The study’s primary endpoint is resolution of fatigue at Day 90 compared with baseline, using a patient-reported outcome measure. The company states that the study may enroll and treat up to 100 patients, with the goal of completing at least 16 patients whose Babesia infection is confirmed at baseline using validated molecular tests.

Radar reading: $SXTP has a real catalyst because the DSMB allowed the trial to continue after early safety review. But the signal is safety/continuation, not efficacy. The market can still react strongly because the company is small and the disease area is underdeveloped.

Why babesiosis matters as a niche biotech theme

Babesiosis is a tick-borne illness caused by Babesia parasites that infect red blood cells. Symptoms can include fever, chills, sweats and fatigue, and severe cases can be life-threatening in elderly or immunosuppressed patients. 60 Degrees Pharma says no FDA-approved treatment or vaccine exists specifically for babesiosis. Tafenoquine is currently FDA-approved for malaria prophylaxis under the ARAKODA brand, but it is not approved by the FDA for the treatment or prevention of babesiosis.

This is where the investment thesis becomes interesting but risky. If the B-FREE program can demonstrate a credible signal in chronic babesiosis with severe fatigue, the company may have a differentiated infectious-disease story. But until stronger data arrive, this remains a small-company development program in an indication where disease definition, testing, patient selection and regulatory path are all important variables.

What looks positive

The independent DSMB identified no safety concerns in the first six patients through Day 30 and recommended study continuation, keeping the Phase 2 program alive and moving.

What keeps risk high

The review covers only early safety data from six patients. It does not prove clinical efficacy, and tafenoquine remains unapproved for babesiosis.

$SXTP trading interpretation

$SXTP belongs in the radar because it has the kind of small-cap clinical update that can generate volatility: DSMB continuation, infectious disease, tafenoquine, severe fatigue and an under-served tick-borne disease. The right classification is “micro-cap infectious-disease safety continuation watch.” The next meaningful proof point is not the DSMB green light itself; it is whether Day 90 fatigue outcomes, molecular confirmation data and future safety updates build a stronger clinical case.

$MODD — Modular Medical: Commercial Rollout Plus FDA Software-Enhancement Submission

Modular Medical is not a classic biotech company. It is a diabetes medical device company, and that distinction matters. Still, $MODD fits today’s radar because it has a real FDA/commercial milestone sequence around Pivot, its tubeless insulin patch pump. The company recently moved from clearance to commercial availability and first patient use, and on July 1 it announced a new FDA submission covering software enhancements for Pivot.

The core Pivot form factor received FDA 510(k) clearance in April 2026. Modular Medical then announced that the Pivot tubeless insulin patch pump was commercially available in the United States on June 24, describing the milestone as the start of real-world patient use and the company’s transition toward a commercial-stage medical device business. On July 1, the company announced submission to the FDA of software enhancements intended to provide more customization options, user-interface improvements and other software upgrades.

That combination changes the story. $MODD is no longer only a “can this device get cleared?” name. It is now a “can this cleared device gain adoption and improve through iterative software upgrades?” name. That is a more execution-heavy setup and less binary than a single clinical readout, but it can still be highly volatile because medical device micro-caps often trade sharply around FDA and commercial milestones.

Radar reading: $MODD should be treated as a medtech execution and FDA software-review watch. The core device is already cleared and in the market; the new catalyst is whether software enhancements can improve usability and support broader adoption.

Why Pivot is trying to carve out a different diabetes-device niche

Pivot is designed for insulin-dependent adults who remain on multiple daily injections and have been hesitant to adopt traditional pumps because of cost, complexity or usability friction. Modular Medical refers to this patient group as “almost-pumpers.” The company has described Pivot as a removable two-part tubeless patch pump with a 3 mL reservoir, smartphone connectivity and a simpler user experience.

The commercial opportunity is attractive on paper, but the proof now shifts to adoption. Medical device success depends on much more than FDA clearance. The company needs physician-office uptake, training efficiency, reimbursement progress, manufacturing reliability, patient retention and favorable real-world feedback. The July 1 software-enhancement submission is relevant because user experience and customization can directly influence adoption in diabetes technology.

What looks positive

Pivot is FDA-cleared, commercially available, in early real-world use and now has a submitted software-enhancement package intended to improve customization and user interface.

What needs monitoring

Commercial availability is not the same as broad adoption. Investors need FDA feedback, patient-use data, reimbursement clues and evidence that rollout can scale beyond early users.

$MODD trading interpretation

$MODD is a different kind of radar name. It is not a binary drug trial. It is a commercial-stage medtech story trying to build momentum around a newly available device and a software upgrade roadmap. The best version of the thesis is that Pivot can address a real usability gap among insulin-dependent adults who are not traditional pump adopters. The weak version is that clearance and early use do not translate into meaningful revenue scale. The right classification is “early commercial medtech execution watch with FDA software-review upside.”

Relative Ranking: Which Story Is Strongest Today?

If we rank the four names by immediate headline strength, $CANF comes first because it has the cleanest classic biotech catalyst: Phase 2a, pancreatic cancer, primary safety endpoint and survival observations. $ABVX comes second because it is the strongest late-stage development story, but the offering overhang makes the near-term tape more complicated. $MODD comes third because it combines FDA clearance, commercial availability, first patient use and a fresh FDA software-enhancement submission. $SXTP comes fourth because the DSMB recommendation is positive, but it is still early safety-continuation news rather than efficacy proof.

Best headline $CANF
Best late-stage setup $ABVX
Best medtech execution watch $MODD
Highest micro-cap clinical risk $SXTP

Operational Watchlist for Traders

  • $CANF: watch whether the move holds after the first momentum wave; the key follow-up is whether the company provides a clear Phase 2b combination protocol, timeline or partnership angle.
  • $ABVX: watch ADS offering pricing, resumed Euronext trading, Nasdaq reaction and whether investors refocus on the Q4 2026 NDA path after financing terms are digested.
  • $SXTP: watch enrollment, Day 90 fatigue endpoint language, molecular confirmation rates and future DSMB or interim updates; avoid treating safety continuation as proven efficacy.
  • $MODD: watch FDA feedback on the software-enhancement submission, early patient feedback, physician-office rollout, reimbursement clues and Q4 commercial expansion signals.

Final View: A Useful Radar Day, But Not a One-Size-Fits-All Tape

Today’s biotech radar is useful because the four names do not overlap. $CANF is the fast oncology headline. $ABVX is the late-stage regulatory setup with financing noise. $SXTP is the speculative infectious-disease continuation watch. $MODD is the diabetes medtech execution story with a fresh FDA software submission.

For readers who follow biotech momentum, $CANF is the obvious first screen because the headline can attract immediate volume. For readers who prefer late-stage clinical quality, $ABVX remains the most developed program in the group, although offering terms matter. For readers who like obscure infectious-disease themes, $SXTP is worth tracking but should be treated as early and risky. For readers who want a commercialization angle instead of a binary drug readout, $MODD offers the cleanest medtech execution watch.

The best conclusion is simple: today’s biotech tape has real catalysts, but each one needs its own risk label. The job is to separate headline excitement from actual de-risking.

Sources and Further Reading

Educational disclaimer: This content is for informational and educational purposes only and does not constitute financial advice, investment advice, medical advice, a recommendation to buy or sell securities, or a solicitation to engage in any transaction. Biotech and medtech stocks can be highly volatile, especially around clinical, regulatory, financing and commercialization events. Always verify primary sources, company filings, trial registries and regulatory documents before making any investment decision.